Update in Diagnostic Imaging of the Thymus and Anterior Mediastinal Masses
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Advancement in Diagnostic Imaging of Thymic Tumors
cancers Commentary Advancement in Diagnostic Imaging of Thymic Tumors Francesco Gentili 1,*, Ilaria Monteleone 2, Francesco Giuseppe Mazzei 1, Luca Luzzi 3, Davide Del Roscio 2, Susanna Guerrini 1 , Luca Volterrani 2 and Maria Antonietta Mazzei 2 1 Unit of Diagnostic Imaging, Department of Radiological Sciences, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy; [email protected] (F.G.M.); [email protected] (S.G.) 2 Unit of Diagnostic Imaging, Department of Medical, Surgical and Neuro Sciences and of Radiological Sciences, University of Siena, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy; [email protected] (I.M.); [email protected] (D.D.R.); [email protected] (L.V.); [email protected] (M.A.M.) 3 Thoracic Surgery Unit, Department of Medical, Surgical and Neuro Sciences, University of Siena, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy; [email protected] * Correspondence: [email protected] Simple Summary: Diagnostic imaging is pivotal for the diagnosis and staging of thymic tumors. It is important to distinguish thymoma and other tumor histotypes amenable to surgery from lymphoma. Furthermore, in cases of thymoma, it is necessary to differentiate between early and advanced disease before surgery since patients with locally advanced tumors require neoadjuvant chemotherapy for improving survival. This review aims to provide to radiologists a full spectrum of findings of thymic neoplasms using traditional and innovative imaging modalities. Abstract: Thymic tumors are rare neoplasms even if they are the most common primary neoplasm of the anterior mediastinum. In the era of advanced imaging modalities, such as functional MRI, dual- Citation: Gentili, F.; Monteleone, I.; Mazzei, F.G.; Luzzi, L.; Del Roscio, D.; energy CT, perfusion CT and radiomics, it is possible to improve characterization of thymic epithelial Guerrini, S.; Volterrani, L.; Mazzei, tumors and other mediastinal tumors, assessment of tumor invasion into adjacent structures and M.A. -
Diagnostic Approach to Congenital Cystic Masses of the Neck from a Clinical and Pathological Perspective
Review Diagnostic Approach to Congenital Cystic Masses of the Neck from a Clinical and Pathological Perspective Amanda Fanous 1,†, Guillaume Morcrette 2,†, Monique Fabre 3, Vincent Couloigner 1,4 and Louise Galmiche-Rolland 5,* 1 Pediatric Otolaryngology-Head and Neck Surgery, AP-HP, Hôpital Universitaire Necker Enfants Malades, 75015 Paris, France; [email protected] (A.F.); [email protected] (V.C.) 2 Department of Pediatric Pathology, AP-HP, Hôpital Robert Debré, 75019 Paris, France; [email protected] 3 Department of Pathology, AP-HP, Hôpital Universitaire Necker Enfants Malades, Université Paris Descartes, 75015 Paris, France; [email protected] 4 Faculté de Médecine, Université de Paris, 75015 Paris, France 5 Department of Pathology, University Hospital of Nantes, 44000 Nantes, France * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Background: neck cysts are frequently encountered in pediatric medicine and can present a diagnostic dilemma for clinicians and pathologists. Several clinical items enable to subclassify neck cyst as age at presentation, anatomical location, including compartments and fascia of the neck, and radiological presentation. Summary: this review will briefly describe the clinical, imaging, pathologi- cal and management features of (I) congenital and developmental pathologies, including thyroglossal duct cyst, branchial cleft cysts, dermoid cyst, thymic cyst, and ectopic thymus; (II) vascular malforma- Citation: Fanous, A.; Morcrette, G.; Fabre, M.; Couloigner, V.; tions, including lymphangioma. Key Messages: pathologists should be familiar with the diagnostic Galmiche-Rolland, L. Diagnostic features and clinicopathologic entities of these neck lesions in order to correctly diagnose them and Approach to Congenital Cystic to provide proper clinical management. -
Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors
Published OnlineFirst February 26, 2013; DOI: 10.1158/1078-0432.CCR-12-3260 Clinical Cancer Human Cancer Biology Research Copy Number Aberrations of Genes Regulating Normal Thymus Development in Thymic Epithelial Tumors Iacopo Petrini1, Yisong Wang1, Paolo A. Zucali3, Hye Seung Lee1,4, Trung Pham1, Donna Voeller1, Paul S. Meltzer2, and Giuseppe Giaccone1 Abstract Purposes: To determine whether the deregulation of genes relevant for normal thymus development can contribute to the biology of thymic epithelial tumors (TET). Experimental Design: Using array comparative genomic hybridization, we evaluated the copy number aberrations of genes regulating thymus development. The expression of genes most commonly involved in copy number aberrations was evaluated by immunohistochemistry and correlated with patients’ outcome. Correlation between FOXC1 copy number loss and gene expression was determined in a confirmation cohort. Cell lines were used to test the role of FOXC1 in tumors. Results: Among 31 thymus development-related genes, PBX1 copy number gain and FOXC1 copy number loss were presented in 43.0% and 39.5% of the tumors, respectively. Immunohistochemistry on a series of 132 TETs, including those evaluated by comparative genomic hybridization, revealed a correlation between protein expression and copy number status only for FOXC1 but not for PBX1. Patients with FOXC1- negative tumors had a shorter time to progression and a trend for a shorter disease-related survival. The correlation between FOXC1 copy number loss and mRNA expression was confirmed in a separate cohort of 27 TETs. Ectopic FOXC1 expression attenuated anchorage-independent cell growth and cell migration in vitro. Conclusion: Our data support a tumor suppressor role of FOXC1 in TETs. -
Einstein Healthcare Network Cancer Center Active
EINSTEIN HEALTHCARE NETWORK CANCER CENTER ACTIVE CLINICAL TRIALS 1 TABLE OF CONTENTS PAGE Studies by Organ/System 3 Brain 4 - 6 Breast – Neoadjuvant/Adjuvant 6 Breast – Advanced/Metastatic 7-8 Gastrointestinal – Colorectal – Adjuvant 9 Gastrointestinal –Advanced, Metastatic 10 Gastrointestinal –Hepatocellular 11 Gastrointestinal –Pancreatic 12-13 Genitourinary – Prostate 14 Gynecological 15-16 Head and Neck 17 Myeloma 18-20 Lung – NSCLC 21-22 Lung – SCLC/Thymoma, Thymic Carcinoma/Mesothelioma 23-24 Supportive care 25 Multiple cancer diagnoses 26 Trials pending activation 27 ECOG Path. Coordinating Ctr Information “NEW” 10/24/2014 2 BRAIN PROTOCOL CONTACTS Radiation Oncology Investigator – Kenneth Zeitzer, MD 215-456-6280 Coordinator – Jeff Mealey, RN 215-456-6316 No active studies at this time. 3 BREAST PROTOCOL CONTACTS MEDICAL ONCOLOGY Investigator – Mark S. Morginstin, DO 215-456-3880 Coordinator – Joann R. Ackler, RN, OCN, CCRP 215-456-8295 RADIATION ONCOLOGY Investigator – Angelica T. Montesano, MD 215-456-6280 Coordinator – Jeff Mealy, RN 215-456-6316 STUDY# TITLE and ELIGIBILITY CRITERIA THERAPY ADJUVANT NRG BR-003/ A Randomized Phase III Trial of Adjuvant Therapy Arm 1: CIRB-005 Comparing Doxorubicin Plus Cyclophosphamide Followed by Doxorubicin 60 mg/M2 IV Weekly Paclitaxel with or without Carboplatin for Node- Cyclophosphamide 600 mg/m2 IV # Pts: _____ Positive or High-Risk Node Negative Invasive Breast Cancer Q 2 Weeks X 4 cycles Eligibility: Unilateral breast IDC: pT1-3; pN0 – pN3b, Followed by: underwent mastectomy or clear margins on lumpectomy/re- Paclitaxel 80 mg/m2 IV weekly x 12 doses excision; ER, PR, & HER2 negative (please see pgs. 14-15 of protocol for specifics). -
Sonography of the Salivary Glands and Soft Tissue Lesions of the Neck
Ultrasound of the liver …. 02.05.2011 08:38 1 EFSUMB – European Course Book Editor: Christoph F. Dietrich Sonography of the salivary glands and soft tissue lesions of the neck Norbert Gritzmann1, Susanne A. Quis1, Rhodri M. Evans2 3Dr. Rhodri M Evans. Consultant Radiologist and Senior Clinical Tutor, Morriston Hospital, Swansea University Medical School, Clinical Director Diagnostics, Abertawe Bro Morgannwg University LHB. E mail: [email protected] Corresponding author1: Univ. Prof. Dr. Norbert Gritzmann Gruppenpraxis für Radiologie Esslinger Hauptstr.89 1220 Vienna Austria Tel 0043 676 84 04 64 Fax 0043 676 84 04 64 email: [email protected] Ultrasound of the liver …. CFD 02.05.2011 08:38 2 Content Content ....................................................................................................................................... 2 Topography and sonographic anatomy of the salivary glands................................................... 3 Sonographic anatomy............................................................................................................. 3 Parotid gland ...................................................................................................................... 3 Color Duplex Doppler.................................................................................................... 3 Submandibular gland.......................................................................................................... 4 Sublingual gland................................................................................................................ -
Malignant Ectopic Thymoma in the Neck: a Case Report
AJNR Am J Neuroradiol 20:1747±1749, October 1999 Case Report Malignant Ectopic Thymoma in the Neck: A Case Report Jung Im Jung, Hak Hee Kim, Seog Hee Park, and Youn Soo Lee Summary: We report a case of malignant ectopic thymoma phytic reddish mass in the left tongue base. Contrast-enhanced in the neck. Contrast-enhanced CT of the neck showed a CT of the neck showed an ill-de®ned, 2 3 3-cm, densely en- well-de®ned inhomogeneously enhancing mass in the left hancing mass in the left tongue base (Fig 1C). Multiple, round, conglomerate lymph nodes with central hypoattenuation and a jugulodigastric chain. One year after surgery, the mass had peripherally enhancing rim were noted in the left posterior metastasized to the tongue base, and CT of the neck neck. Biopsy and subsequent surgery, including hemiglossec- showed an ill-de®ned densely enhancing mass with tomy and radical neck dissection, revealed metastatic malig- lymphadenopathy. nant thymoma (Fig 1D±E). After surgery, radiation therapy was administered. The thymus anatomically originates from the su- perior neck during early fetal life and descends to Discussion the mediastinum. During this descent, remnants of Thymus develops from the ventral portion of the thymic tissue occasionally are implanted along the third and fourth pharyngeal pouches. This descends cervical pathway and may appear later as an ectop- into the anterior mediastinum by the sixth week of ic cervical thymus (1). Although rare, malignant gestation. Thymic ectopia results from failure of thymoma may develop from an ectopic thymus (2). this migration. Aberrant nodules of thymic tissue We present a case of malignant thymoma occurring are found in approximately 20% of humans. -
ITMIG Classification of Mediastinal Compartments and Multidisciplinary
This copy is for personal use only. To order printed copies, contact [email protected] 413 CHEST IMAG ITMIG Classification of Mediastinal Compartments and Multidisciplinary I Approach to Mediastinal Masses1 NG Brett W. Carter, MD Marcelo F. Benveniste, MD Division of the mediastinum into specific compartments is ben- Rachna Madan, MD eficial for a number of reasons, including generation of a focused Myrna C. Godoy, MD, PhD differential diagnosis for mediastinal masses identified on imag- Patricia M. de Groot, MD ing examinations, assistance in planning for biopsies and surgical Mylene T. Truong, MD procedures, and facilitation of communication between clinicians Melissa L. Rosado-de-Christenson, MD in a multidisciplinary setting. Several classification schemes for Edith M. Marom, MD the mediastinum have been created and used to varying degrees in clinical practice. Most radiology classifications have been based Abbreviations: FDG = fluorodeoxyglucose, on arbitrary landmarks outlined on the lateral chest radiograph. A ITMIG = International Thymic Malignancy In- terest Group, JART = Japanese Association for new scheme based on cross-sectional imaging, principally multi- Research on the Thymus, SUVmax = maximal detector computed tomography (CT), has been developed by the standardized uptake value International Thymic Malignancy Interest Group (ITMIG) and RadioGraphics 2017; 37:413–436 accepted as a new standard. This clinical division scheme defines Published online 10.1148/rg.2017160095 unique prevascular, visceral, and paravertebral compartments -
Incidental Pleural-Based Pulmonary Lymphangioma CASE REPORT
CASE REPORT Incidental Pleural-Based Pulmonary Lymphangioma Michael G. Benninghoff, DO William U. Todd, MD Rebecca Bascom, MD, MPH Adult benign thoracic lymphangiomas typically present as ondary forms develop in adults as a result of lymphatic channel incidental mediastinal lesions, or, more rarely, as solitary pul- obstruction caused by radiation, surgery, or infection.1 monary nodules. Symptomatic compression of vital struc- Patients with lymphangiomas can be asymptomatic for tures may require lesion resection or sclerotherapy. In the many years and often have symptoms only after vital structures present report, we describe the incidental finding of a soli- are compressed by the lesion. As such, asymptomatic lym- tary pleural-based pulmonary lymphangioma in a 38-year- phangiomas are typically found incidentally on chest radio- old woman with chronic arm and shoulder pain. Positron graphs or computed tomography (CT) scans without any emission tomography revealed that the lesion was highly unique visible characteristics. Although biopsies can identify fluorodeoxyglucose-avid. Biopsy exposed benign tissue malignant or benign lesions, empiric resection is often per- consistent with lymphangioma. After continued radio- formed as a precautionary measure. If surgical means are pur- graphic tests, the lesion was determined to be an unlikely sued, however, it is important to remove the entire lesion to source of the patient’s chronic pain. The present report is, to avoid tumor regrowth. our knowledge, the first published case of solitary pleural- In the present report, we describe a woman who had based pulmonary lymphangioma in the medical literature. chronic pain in her right upper arm and shoulder. A pleural- J Am Osteopath Assoc. -
Pulmonary in Trisomy 18 (T18) and Has Been Described Also in Several Disorders Other Than T18
ANNUAL MEETING ABSTRACTS 449A 1867 Infections in a Children’s Hospital Autopsy Population abstract, is useful and may serve as a guideline to define CH, with linear regression +20% J Springer, R Craver. Louisiana State University Health Science Center, New Orleans, of T18 cases and/or linear regression -20% of control cases being the borderline for CH. LA. Background: Despite advances in antimicrobial therapy, infections/inflammatory 1869 Expression of Disialoganglioside GD2 in Neuroblastomas of lesions may frequently cause or contribute to death in children. Patients Treated with Immunotherapy Design: We retrospectively reviewed all autopsies performed at a children’s hospital T Terzic, P Teira, S Cournoyer, M Peuchmaur, H Sartelet. Centre Hospitalier from 1986-2009 and categorized infectious complications as 1)underlying cause Universitaire Sainte-Justine, Montreal, QC, Canada; Hopital Universitaire Robert- of death,2) mechanism of death complicating another underlying cause of death,3) Debre, Paris, France. contributing to death 4) agonal or infections immediately before death 5) incidental. Background: Neuroblastoma, a malignant neoplasm of the sympathetic nervous Infectious complications were then separated into 3-8 year groups to identify trends system, is one of the most aggressive pediatric cancers with a tendency for widespread over the years. dissemination, relapse and a poor long term survival, despite intensive multimodal Results: There were 1369 deaths over 24 years, 608 (44%) underwent autopsy at treatments. Recent use of immunotherapy (a chimeric human-murine monoclonal the hospital, another 122 (8.9%) were coroner’s cases not performed at the hospital. antibody ch14.18 directed against a tumor-associated antigen GD2, a disialoganglioside) There were 691 infectious conditions in 401 children (66%, 1.72 infections/infected to treat minimal residual disease has shown improvement in event-free and overall patient).There were no differences in the percentage of autopsies with infections over survival of high-risk neuroblastomas. -
Redalyc.POSTERS EXPOSTOS
Revista Portuguesa de Pneumología ISSN: 0873-2159 [email protected] Sociedade Portuguesa de Pneumologia Portugal POSTERS EXPOSTOS Revista Portuguesa de Pneumología, vol. 23, núm. 3, noviembre, 2017 Sociedade Portuguesa de Pneumologia Lisboa, Portugal Disponível em: http://www.redalyc.org/articulo.oa?id=169753668003 Como citar este artigo Número completo Sistema de Informação Científica Mais artigos Rede de Revistas Científicas da América Latina, Caribe , Espanha e Portugal Home da revista no Redalyc Projeto acadêmico sem fins lucrativos desenvolvido no âmbito da iniciativa Acesso Aberto Document downloaded from http://www.elsevier.es, day 06/12/2017. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. POSTERS EXPOSTOS PE 001 PE 002 A PLEASANT FINDING MALIGNANT CHEST PAIN A Pais, AI Coutinho, M Cardoso, A Pignatelli, C Bárbara A Pais, C Pereira, C Antunes, V Pereira, AI Coutinho, A Feliciano, Centro Hospitalar de Lisboa Norte C Quadros, A Ribeiro, L Carvalho, C Bárbara Centro Hospitalar de Lisboa Norte Key-words: mass, debridement, hamartoma Key-words: pain, S100, sarcoma 37-year-old male patient, salesman. Sporadic smoker. With a past history of allergic rhinitis and chronic gastritis. With no usual 26-year-old male patient, supermarket employee. Smoker of 10 medication. In January 2017, he was diagnosed with a respiratory pack-year. Past history of bronchial asthma in childhood. No rel - infection, having completed ten days of empirical antibiotic ther - evant family history. Without usual ambulatory medication. With apy with amoxicillin / clavulanic acid, with clinical improvement. a history of dry cough and chest pain in the posterior region of In May 2017, he underwent thoracic xray, which revealed homoge - the left hemithorax, for about two years, having had at that time, neous opacity of triangular morphology in the middle lobe of the chest X-ray without pathological findings, and the clinical picture right lung. -
(NCCN Guidelines®) Thymomas and Thymic Carcinomas
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Thymomas and Thymic Carcinomas Version 2.2019 — March 11, 2019 NCCN.org Continue Version 2.2019, 03/11/19 © 2019 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index NCCN Guidelines Version 2.2019 Table of Contents Thymomas and Thymic Carcinomas Discussion *David S. Ettinger, MD/Chair † Ramaswamy Govindan, MD † Sandip P. Patel, MD ‡ † Þ The Sidney Kimmel Comprehensive Siteman Cancer Center at Barnes- UC San Diego Moores Cancer Center Cancer Center at Johns Hopkins Jewish Hospital and Washingtn University School of Medicine Karen Reckamp, MD, MS † ‡ *Douglas E. Wood, MD/Vice Chair ¶ City of Hope National Medical Center Fred Hutchinson Cancer Research Matthew A. Gubens, MD, MS † Center/Seattle Cancer Care Alliance UCSF Helen Diller Family Gregory J. Riely, MD, PhD † Þ Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Dara L. Aisner, MD, PhD ≠ University of Colorado Cancer Center Mark Hennon, MD ¶ Steven E. Schild, MD § Roswell Park Cancer Institute Mayo Clinic Cancer Center Wallace Akerley, MD † Huntsman Cancer Institute Leora Horn, MD, MSc † Theresa A. Shapiro, MD, PhD Þ at the University of Utah Vanderbilt-Ingram Cancer Center The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Jessica Bauman, MD ‡ † Rudy P. Lackner, MD ¶ Fox Chase Cancer Center Fred & Pamela Buffett Cancer Center James Stevenson, MD † Case Comprehensive Cancer Center/ Ankit Bharat, MD ¶ Michael Lanuti, MD ¶ University Hospitals Seidman Cancer Center Robert H. Lurie Comprehensive Cancer Massachusetts General Hospital Cancer Center and Cleveland Clinic Taussig Cancer Institute Center of Northwestern University Ticiana A. -
Cigna Chest Imaging Guidelines
Cigna Medical Coverage Policies – Radiology Chest Imaging Guidelines Effective February 1, 2021 ____________________________________________________________________________________ Instructions for use The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer’s particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of: 1. The terms of the applicable benefit plan document in effect on the date of service 2. Any applicable laws and regulations 3. Any relevant collateral source materials including coverage policies 4. The specific facts of the particular situation Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines. This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna. These guidelines include procedures eviCore does not review for Cigna.